Design and Implementation of NK Cell-Based Immunotherapy to Overcome the Solid Tumor Microenvironment

被引:26
作者
Navin, Ishwar [1 ,2 ]
Lam, Michael T. [3 ,4 ]
Parihar, Robin [1 ,2 ,3 ,4 ,5 ]
机构
[1] Baylor Coll Med, Dept Immunol & Microbiol, Houston, TX 77030 USA
[2] Texas Childrens Hosp, Baylor Coll Med, Houston Methodist Hosp, Ctr Cell & Gene Therapy, Houston, TX 77030 USA
[3] Baylor Coll Med, Med Scientist Training Program, Houston, TX 77030 USA
[4] Baylor Coll Med, Translat Biol & Mol Med Program, Houston, TX 77030 USA
[5] Texas Childrens Hosp, Dept Pediat, Sect Hematol Oncol, Houston, TX 77030 USA
关键词
NK cell; solid tumor; tumor microenvironment (TME); immunotherapy; cell therapy; chimeric antigen receptor (CAR); NATURAL-KILLER-CELLS; GROWTH-FACTOR-BETA; CHIMERIC ANTIGEN RECEPTOR; PHASE-I TRIAL; SUPPRESSOR-CELLS; TGF-BETA; T-CELLS; CORD BLOOD; REGULATORY-CELLS; GAMMA PRODUCTION;
D O I
10.3390/cancers12123871
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Cell therapy over the last few years has revolutionized the treatment of blood cancers. However, efficacy against cancers of solid organs remains limited. These cancers pose a major challenge to the success of cell therapy by generating a suppressive environment that inhibits immunity. We review current efforts to improve the potency of natural killer (NK) cell therapy in the tumor microenvironment. The successful application of these approaches will lead to more effective treatment options and improve clinical outcomes for patients with solid cancers. Natural killer (NK) cells are innate immune effectors capable of broad cytotoxicity via germline-encoded receptors and can have conferred cytotoxic potential via the addition of chimeric antigen receptors. Combined with their reduced risk of graft-versus-host disease (GvHD) and cytokine release syndrome (CRS), NK cells are an attractive therapeutic platform. While significant progress has been made in treating hematological malignancies, challenges remain in using NK cell-based therapy to combat solid tumors due to their immunosuppressive tumor microenvironments (TMEs). The development of novel strategies enabling NK cells to resist the deleterious effects of the TME is critical to their therapeutic success against solid tumors. In this review, we discuss strategies that apply various genetic and non-genetic engineering approaches to enhance receptor-mediated NK cell cytotoxicity, improve NK cell resistance to TME effects, and enhance persistence in the TME. The successful design and application of these strategies will ultimately lead to more efficacious NK cell therapies to treat patients with solid tumors. This review outlines the mechanisms by which TME components suppress the anti-tumor activity of endogenous and adoptively transferred NK cells while also describing various approaches whose implementation in NK cells may lead to a more robust therapeutic platform against solid tumors.
引用
收藏
页码:1 / 22
页数:22
相关论文
共 171 条
[1]   Genetic reprogramming for NK cell cancer immunotherapy with CRISPR/Cas9 [J].
Afolabi, Lukman O. ;
Adeshakin, Adeleye O. ;
Sani, Musbahu M. ;
Bi, Jiacheng ;
Wan, Xiaochun .
IMMUNOLOGY, 2019, 158 (02) :63-69
[2]   Idelalisib Rescues Natural Killer Cells from Monocyte-Induced Immunosuppression by Inhibiting NOX2-Derived Reactive Oxygen Species [J].
Akhiani, Ali A. ;
Hallner, Alexander ;
Kiffin, Roberta ;
Aydin, Ebru ;
Werlenius, Olle ;
Aurelius, Johan ;
Martner, Anna ;
Thoren, Fredrik B. ;
Hellstrand, Kristoffer .
CANCER IMMUNOLOGY RESEARCH, 2020, 8 (12) :1532-1541
[3]  
Albertini Mark R, 2005, Cancer Chemother Biol Response Modif, V22, P789
[4]   Transforming growth factor-β and peripheral regulatory cells are negatively correlated with the overall survival of hepatocellular carcinoma [J].
An, Yang ;
Gao, Song ;
Zhao, Wen-Chao ;
Qiu, Bao-An ;
Xia, Nian-Xin ;
Zhang, Peng-Jun ;
Fan, Zhen-Ping .
WORLD JOURNAL OF GASTROENTEROLOGY, 2018, 24 (25) :2733-2740
[5]   Selective apoptosis of natural killer-cell tumours by L-asparaginase [J].
Ando, M ;
Sugimoto, K ;
Kitoh, T ;
Sasaki, M ;
Mukai, K ;
Ando, J ;
Egashira, M ;
Schuster, SM ;
Oshimi, K .
BRITISH JOURNAL OF HAEMATOLOGY, 2005, 130 (06) :860-868
[6]   Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells [J].
Andre, Pascale ;
Denis, Caroline ;
Soulas, Caroline ;
Bourbon-Caillet, Clarisse ;
Lopez, Julie ;
Arnoux, Thomas ;
Blery, Mathieu ;
Bonnafous, Cecile ;
Gauthier, Laurent ;
Morel, Ariane ;
Rossi, Benjamin ;
Remark, Romain ;
Breso, Violette ;
Bonnet, Elodie ;
Habif, Guillaume ;
Guia, Sophie ;
Lalanne, Ana Ines ;
Hoffmann, Caroline ;
Lantz, Olivier ;
Fayette, Jerome ;
Boyer-Chammard, Agnes ;
Zerbib, Robert ;
Dodion, Pierre ;
Ghadially, Hormas ;
Jure-Kunkel, Maria ;
Morel, Yannis ;
Herbst, Ronald ;
Narni-Mancinelli, Emilie ;
Cohen, Roger B. ;
Vivier, Eric .
CELL, 2018, 175 (07) :1731-+
[7]  
[Anonymous], 2020, INT J MOL SCI
[8]  
[Anonymous], 2020, FRONT IMMUNOL
[9]  
[Anonymous], 2015, SCI REP UK
[10]   Kinetics of Early T Cell Receptor Signaling Regulate the Pathway of Lytic Granule Delivery to the Secretory Domain [J].
Beal, Allison M. ;
Anikeeva, Nadia ;
Varma, Rajat ;
Cameron, Thomas O. ;
Vasiliver-Shamis, Gaia ;
Norris, Philip J. ;
Dustin, Michael L. ;
Sykulev, Yuri .
IMMUNITY, 2009, 31 (04) :632-642